Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results

Dow Jones

05/04

By Adriano Marchese

Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment.

Shares rose 14.6% in ahead of the morning bell to $144.

The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA.

The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint.

Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug.

After that, the company will also share the data with regulators in other countries, it said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

May 04, 2026 07:30 ET (11:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2632930986"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2632930986\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2632930986?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632930986","market":"other","top_or_hot":-1,"title":"Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment. \n</p>\n<p>\n  Shares rose 14.6% in ahead of the morning bell to $144. \n</p>\n<p>\n  The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA. \n</p>\n<p>\n  The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint. \n</p>\n<p>\n  Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug. \n</p>\n<p>\n  After that, the company will also share the data with regulators in other countries, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 04, 2026 07:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelcuity Shares Climb on Positive Breast-Cancer Drug Trial Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-04 19:30</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment. \n</p>\n<p>\n  Shares rose 14.6% in ahead of the morning bell to $144. \n</p>\n<p>\n  The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA. \n</p>\n<p>\n  The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint. \n</p>\n<p>\n  Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug. \n</p>\n<p>\n  After that, the company will also share the data with regulators in other countries, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 04, 2026 07:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2632930986","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632930986","pubTimestamp":1777894200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment.Shares rose 14.6% in ahead of the morning bell to $144.The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA.The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint.Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug.After that, the company will also share the data with regulators in other countries, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CELC":"Celcuity Inc"},"translate_title":"Celcuity股价因乳腺癌药物试验结果积极而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment. \n\n\n  Shares rose 14.6% in ahead of the morning bell to $144. \n\n\n  The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA. \n\n\n  The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint. \n\n\n  Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug. \n\n\n  After that, the company will also share the data with regulators in other countries, it said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 07:30 ET (11:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}